Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin in prostate cancer patients receiving new-generation androgen therapy
2022-000082-41Phase 4Active
- Sponsor
- Fundación para la Investigación en Urología
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of pitavastatin in prostate cancer (PCa) (2 arms), sponsored by Fundación para la Investigación en Urología. Primary endpoints: Metastasis-free survival and Radiological progression-free survival. Started Jan 2022; status: active.
02
Drugs
pitavastatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-000082-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000082-41.